Gowda Ramesh M, Punukollu Gopikrishna, Khan Ijaz A, Patlola Raghotham R, Tejani Furqan H, Cosme-Thormann Braulio F, Vasavada Balendu C, Sacchi Terrence J
Division of Cardiology, Long Island College Hospital, Brooklyn, NY, USA.
Am J Ther. 2002 Nov-Dec;9(6):527-9. doi: 10.1097/00045391-200211000-00013.
Ibutilide is a class III antiarrhythmic agent used for the termination of atrial fibrillation and atrial flutter. It mainly affects membrane potassium currents and prolongs the cardiac action potential. This effect is reflected as QT interval prolongation on the surface electrocardiogram. Like other drugs that affect potassium currents, ibutilide is prone to induce a malignant ventricular tachycardia, torsade de pointes. We report four cases of torsade de pointes after administration of ibutilide for pharmacologic cardioversion of atrial fibrillation and atrial flutter; three of these cases required direct current cardioversion for termination of torsade de pointes. All four patients were female. We discuss the risk factors for development of ibutilide-induced torsade de pointes.
伊布利特是一种III类抗心律失常药物,用于终止心房颤动和心房扑动。它主要影响膜钾电流并延长心脏动作电位。这种效应在体表心电图上表现为QT间期延长。与其他影响钾电流的药物一样,伊布利特易于诱发恶性室性心动过速——尖端扭转型室速。我们报告了4例在使用伊布利特进行心房颤动和心房扑动药物复律后发生尖端扭转型室速的病例;其中3例需要直流电复律来终止尖端扭转型室速。所有4例患者均为女性。我们讨论了伊布利特诱发尖端扭转型室速的危险因素。